全文获取类型
收费全文 | 11229篇 |
免费 | 795篇 |
国内免费 | 25篇 |
专业分类
耳鼻咽喉 | 77篇 |
儿科学 | 382篇 |
妇产科学 | 254篇 |
基础医学 | 1674篇 |
口腔科学 | 142篇 |
临床医学 | 1315篇 |
内科学 | 2381篇 |
皮肤病学 | 225篇 |
神经病学 | 1456篇 |
特种医学 | 122篇 |
外科学 | 1483篇 |
综合类 | 76篇 |
一般理论 | 14篇 |
预防医学 | 1169篇 |
眼科学 | 96篇 |
药学 | 581篇 |
中国医学 | 20篇 |
肿瘤学 | 582篇 |
出版年
2023年 | 66篇 |
2022年 | 121篇 |
2021年 | 301篇 |
2020年 | 175篇 |
2019年 | 311篇 |
2018年 | 318篇 |
2017年 | 219篇 |
2016年 | 260篇 |
2015年 | 263篇 |
2014年 | 359篇 |
2013年 | 535篇 |
2012年 | 779篇 |
2011年 | 790篇 |
2010年 | 465篇 |
2009年 | 408篇 |
2008年 | 663篇 |
2007年 | 752篇 |
2006年 | 728篇 |
2005年 | 700篇 |
2004年 | 656篇 |
2003年 | 613篇 |
2002年 | 558篇 |
2001年 | 176篇 |
2000年 | 150篇 |
1999年 | 139篇 |
1998年 | 138篇 |
1997年 | 102篇 |
1996年 | 111篇 |
1995年 | 80篇 |
1994年 | 75篇 |
1993年 | 81篇 |
1992年 | 96篇 |
1991年 | 80篇 |
1990年 | 79篇 |
1989年 | 65篇 |
1988年 | 55篇 |
1987年 | 54篇 |
1986年 | 40篇 |
1985年 | 33篇 |
1984年 | 44篇 |
1983年 | 25篇 |
1982年 | 44篇 |
1981年 | 49篇 |
1980年 | 25篇 |
1979年 | 22篇 |
1978年 | 29篇 |
1977年 | 24篇 |
1976年 | 19篇 |
1973年 | 18篇 |
1971年 | 18篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
Rizzo Manglio Miguel Bluthgen Mara Virginia Recondo Gonzalo Naveira Martin Perfetti Aldo Rizzi Florencia Kuzminin Alejandro Faura Victoria Cerini Matas Videla Alejandro Silva Carlos Lupinacci Lorena Minatta Nicols 《International journal of clinical oncology / Japan Society of Clinical Oncology》2021,26(6):1057-1064
International Journal of Clinical Oncology - Immune-checkpoint inhibitors (ICIs) are standard treatments for metastatic non-small cell lung cancer (NSCLC). Patients with poor performance status... 相似文献
2.
Caroline E. Sloan Judy Zhong Dinushika Mohottige Rasheeda Hall Clarissa J. Diamantidis Leight E. Boulware Virginia Wang 《Seminars in dialysis》2020,33(6):440-448
Caring for patients with end-stage kidney disease (ESKD) in the United States is challenging, due in part to the complex epidemiology of the disease's progression as well as the ways in which care is delivered. As CKD progresses toward ESKD, the number of comorbidities increases and care involves multiple healthcare providers from multiple subspecialties. This occurs in the context of a fragmented US healthcare delivery system that is traditionally siloed by provider specialty, organization, as well as systems of payment and administration. This article describes the role of care fragmentation in the delivery of optimal ESKD care and identifies research gaps in the evidence across the continuum of care. We then consider the impact of care fragmentation on ESKD care from the patient and health system perspectives and explore opportunities for system-level interventions aimed at improving care for patients with ESKD. 相似文献
3.
4.
5.
Miguel A. Sanz Pau Montesinos Haesook T. Kim Guillermo J. Ruiz-Argüelles María S. Undurraga María R. Uriarte Lem Martínez Rafael H. Jacomo Homero Gutiérrez-Aguirre Raul A. M. Melo Rosane Bittencourt Ricardo Pasquini Katia Pagnano Evandro M. Fagundes Edo Vellenga Alexandra Holowiecka Ana J. González-Huerta Pascual Fernández Javier De la Serna Salut Brunet Elena De Lisa José González-Campos José M. Ribera Isabel Krsnik Arnold Ganser Nancy Berliner Raul C. Ribeiro Francesco Lo-Coco Bob L?wenberg Eduardo M. Rego 《Annals of hematology》2015,94(8):1347-1356
6.
7.
Dolores Herreros Mariano García-Arranz Isabel Pascual Damián García-Olmo 《Experimental dermatology》2006,15(6):482-482
Purpose: To evaluate all consecutive patients treated with infliximab for hidradenitis suppurativa (HS).
Patients and methods: Within 1 year, all consecutive patients seen in our department for HS (1) resistant to usual medical therapies (2) which could not be easily cured by surgery (3) not treated with new medication within 2 months before inclusion were treated intravenously with infliximab (5 mg/kg) without corticosteroids premedication. Four infusions were planned (week 0, week 2, week 6 and week 10) before the interruption of therapy and follow-up. Clinical activity of HS and quality of life of the patients were assessed immediately before the first, the third and the fourth infusions of infliximab.
Results: Seven patients were included. Five completed the four infusions. Two patients received only three infusions because of severe side effects. The Sartorius score moderately improved with infliximab (mean score at week 0: 94 ± 39, at week 6: 71 ± 38 and at week 10: 83 ± 48). At week 6, patients judged the efficacy of therapy as marked ( n = 1), moderate ( n = 4) or null ( n = 2). At week 10, five patients were evaluated and judged this efficacy as marked ( n = 2), moderate ( n = 2) or null ( n = 1). The mean Skindex-29 score varied from 22 ± 11 (E: 25 ± 9, S: 13 ± 5, F: 28 ± 12) at week 0 to 18 ± 10 (E: 22 ± 8, S: 12 ± 8, F: 22 ± 12) at week 10.
Conclusion: The efficacy of infliximab in severe HS is partial. More experience is needed before finding a place for infliximab in the therapeutic armamentarium for HS. 相似文献
Patients and methods: Within 1 year, all consecutive patients seen in our department for HS (1) resistant to usual medical therapies (2) which could not be easily cured by surgery (3) not treated with new medication within 2 months before inclusion were treated intravenously with infliximab (5 mg/kg) without corticosteroids premedication. Four infusions were planned (week 0, week 2, week 6 and week 10) before the interruption of therapy and follow-up. Clinical activity of HS and quality of life of the patients were assessed immediately before the first, the third and the fourth infusions of infliximab.
Results: Seven patients were included. Five completed the four infusions. Two patients received only three infusions because of severe side effects. The Sartorius score moderately improved with infliximab (mean score at week 0: 94 ± 39, at week 6: 71 ± 38 and at week 10: 83 ± 48). At week 6, patients judged the efficacy of therapy as marked ( n = 1), moderate ( n = 4) or null ( n = 2). At week 10, five patients were evaluated and judged this efficacy as marked ( n = 2), moderate ( n = 2) or null ( n = 1). The mean Skindex-29 score varied from 22 ± 11 (E: 25 ± 9, S: 13 ± 5, F: 28 ± 12) at week 0 to 18 ± 10 (E: 22 ± 8, S: 12 ± 8, F: 22 ± 12) at week 10.
Conclusion: The efficacy of infliximab in severe HS is partial. More experience is needed before finding a place for infliximab in the therapeutic armamentarium for HS. 相似文献
8.
9.
Carlos Ferrer Albiach Antonio Conde Moreno Marta Rodríguez Cordón Virginia Morillo Macías Ana Bouché Babiloni Inmaculada Beato Tortajada Ángel Sánchez Iglesias Alicia Francés Muñoz 《Clinical & translational oncology》2010,12(1):22-26
Hypoxia is related to poor prognosis because it is associated to chemo-and radioresistance. During recent years the evolution
of imaging methods like PET/CT and MRI has meant the appearance of new perspectives with direct implications in radiation
therapy. We discuss previous experiences in staging, planning and in the follow-up process with these techniques for measuring
tumour hypoxia. 相似文献
10.
The greatest benefit of immunosuppression minimization for children may lie in improving patient morbidity, by the elimination of the inherent side effects of steroid and calcineurin inhibitors (CNI). The newer generation of powerful induction and maintenance immunosuppressants offers an option for selected immunosuppression minimization strategies, some of which have been shown to also reduce graft morbidity. Steroid minimization and avoidance in single-center uncontrolled trials have shown early promise and the availability of data from an ongoing randomized, prospective, controlled trial of steroid avoidance in children will provide necessary data to support a practice change for steroid elimination in children. Calcineurin inhibitor minimization and addition of mycophenolate mofetil (MMF) or sirolimus have shown variable improvements in renal function, though suboptimal efficacy and safety with the currently proposed regimes have limited their application. Randomized, prospective studies of steroid and calcineurin inhibitor minimization and/or avoidance are warranted to clearly confirm the short and long-term safety and efficacy of alternative immunosuppression combinations. Linked pharmacokinetic and mechanistic studies within these trials will allow for optimizing drug dosing and monitoring. This article reviews published experience to date with steroid and calcineurin minimization in pediatric renal transplantation and discusses the risks and benefits of these approaches. 相似文献